Cassava Sciences, Inc. (SAVA)
After hours:
- GlobeNewswire
Cassava Sciences Reports First Quarter Financial Results for 2022 and Updates on Phase 3 Clinical Program
- $209.7 Million Cash and Cash Equivalents at March 31, 2022 – - Over 120 Patients Now Enrolled in Phase 3 Program - AUSTIN, Texas, May 05, 2022 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced financial results for the first quarter ended March 31, 2022 and provided a clinical update on its Phase 3 clinical program of simufilam in Alzheimer’s disease. Simufilam is Cassava Sciences’ lead drug candida
- Zacks
Cassava Sciences, Inc. (SAVA) Stock Sinks As Market Gains: What You Should Know
In the latest trading session, Cassava Sciences, Inc. (SAVA) closed at $20.90, marking a -0.99% move from the previous day.
- GlobeNewswire
Cassava Sciences Invited to Participate in B. Riley Securities’ Neuroscience Conference
- Q&A Session at Conference on Wednesday, April 27th at 1:30PM Eastern - AUSTIN, Texas, April 25, 2022 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced that it has been invited to participate in the B. Riley Securities’ Neuroscience Conference, a virtual event taking place on April 27-28, 2022. Remi Barbier, President & CEO, will participate in a Q&A session hosted by B. Riley Securities’ equity rese
